Monitor court filings and any preliminary rulings. Adverse outcome could jeopardize Cardiff's sole clinical-stage asset (onvansertib). The stock may face continued uncertainty until a resolution or material development.
Price Chart
Executive Summary
Cardiff Oncology filed a lawsuit against Nerviano Medical Sciences (NMS) to preemptively challenge NMS's allegation that Cardiff materially breached its onvansertib license agreement. Cardiff seeks injunctive relief to force NMS to continue performing and a declaratory judgment of no breach. The dispute threatens Cardiff's lead asset and introduces significant legal overhang.
Key Facts
- Cardiff filed a lawsuit on May 19, 2026 against Nerviano Medical Sciences (NMS) disputing NMS's material breach allegation.
- The lawsuit seeks injunctive relief requiring NMS to continue performing under the onvansertib license agreement and a declaratory judgment that Cardiff did not breach.
- NMS previously alleged that Cardiff failed to name an NMS employee as a joint inventor on two Cardiff patents and did not agree to file a joint continuation application.
- Cardiff maintains the agreement does not require such actions and that judicial intervention is necessary.
Financial Impact
No specific financial figures disclosed; the onvansertib license is critical to Cardiff's pipeline, so loss of rights could be material.
Risk Factors
- If NMS prevails, Cardiff could lose rights to onvansertib, severely impairing its pipeline.
- Lengthy litigation could distract management and delay clinical programs.
- Patents-in-suit may be challenged, affecting exclusivity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-231040 |
| Document: 0001193125-26-231040-index-headers.html | 0001193125-26-231040 |
| Document: 0001193125-26-231040-index.html | 0001193125-26-231040 |
| Document: 0001193125-26-231040.txt | 0001193125-26-231040 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 3 | $0.8200 | awaiting T+5 | — | $0.8751 (+6.72%) |
Oct 27, 2026 today | 8-K | $0.8200 | awaiting T+5 | — | $0.8751 (+6.72%) |
Sep 22, 2026 5w ago | Institutional Cluster | $1.33 $1.17 | ▲ +12.03% | ▲ +10.84% | $0.8751 (+34.20%) |
Sep 14, 2026 6w ago | 8-K | $1.31 $1.37 | ▲ +4.58% | ▲ +4.47% | $0.8751 (−33.20%) |
Aug 11, 2026 11w ago | Press Release | $0.9900 $0.8979 | ▲ +9.30% | ▲ +8.86% | $0.8751 (+11.61%) |
Jul 16, 2026 14w ago | Insider Cluster | $0.8800 $0.8381 | ▼ −4.76% | ▼ −4.07% | $0.8751 (−0.56%) |
Jul 16, 2026 14w ago | 8-K | $0.8745 $0.8381 | ▲ +4.16% | ▲ +2.49% | $0.8751 (−0.07%) |
Jul 16, 2026 14w ago | 424B5 | $0.8745 $0.8381 | ▲ +4.16% | ▲ +2.49% | $0.8751 (−0.07%) |
Jun 22, 2026 18w ago | Insider Cluster | $1.30 $1.25 | ▼ −3.85% | ▼ −1.78% | $0.8751 (−32.68%) |
Jun 11, 2026 19w ago | Institutional Cluster | $1.59 $1.18 | ▲ +25.79% | ▲ +26.22% | $0.8751 (+44.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers